When: April 28th, 6:00 – 8.30 pm
Where: Crowne Plaza Cabana Hotel, 4290 El Camino Real, Palo Alto, CA 94306
Hear two founder-CEOs present their molecular diagnostics companies:
Bonnie Anderson, CEO, Veracyte
Winnie Wan, CEO, OncoHealth
EPPIC Members and students: $20
EPPIC Non Members: $35
EPPIC Charter Members/Sponsors/Speakers: Complimentary
EPPIC Members: All members who paid either EPPIC 2011 annual membership fee ($50) or EPPIC 2011 Annual conference registration fee ($100 and above) are considered as EPPIC members. For any questions, please e-mail at email@example.com
6.00 – 7.00 pm Networking (wine, snacks and soft drinks are served)
7.00 – 7.30 pm Bonnie Anderson, CEO, Veracyte
7.30 – 8.00 pm Winnie Wan, CEO, OncoHealth
8.00 – 8.30 pm Q&A
Molecular Diagnostics: MDxs are revolutionizing the diagnosis of many diseases, particularly in cancer. Not only do MDx increase the accuracy of the diagnosis, but also they frequently enable targeted treatment of a disease and result in a superior outcome for the patient. Attend this event to hear from two co-founder CEO-entrepreneurs about how they launched their companies.
Veracyte is pioneering the emerging field of molecular cytology. The company has commercialized its first product the Afirma Thyroid FNA Analysis which provides a novel solution for improved accuracy in thyroid nodule diagnosis.
OncoHealth is a protein diagnostic company dedicated to revolutionizing cervical cancer testing and other cancers associated with the Human Papilloma Virus (HPV). The current tests cannot differentiate between benign infection and pre-cancer stages. Consequently the existing tests lead to unnecessary invasive procedures and repeat testing that can be avoided by the novel test. Winnie Wan will speak about launching OncoHealth, obtaining financing and embarking on commercializing the new test.
Bonnie Anderson Cofounder and Chief Executive Officer Veracyte: Bonnie Anderson is the cofounder and Chief Executive Officer of Veracyte, formed in 2008. Her career spans more than 25 years in regulated diagnostics and life science markets where she has led both early-stage businesses as well as mature, global enterprises. Prior to Veracyte, Ms. Anderson provided strategic consulting services to venture capital firms and early-stage businesses following 18 years in leadership positions at Beckman Coulter, including heading the companys global cellular analysis franchises in hematology and flow cytometry. As Vice President of the intrapreneurial start-up Immunomics Operations she successfully positioned the companys novel MHC tetramer technology as a vehicle for drug and vaccine developers to monitor ex-vivo immune response. She currently serves as a member of the Board of Trustees of Keck Graduate Institute of Life Sciences and on the advisory board for Bay Bio. She has also served on the boards of Thymed, GmbH and Women in Biotechnology.
Veracyte is a privately held molecular diagnostics company pioneering the emerging field of molecular cytology. The company develops molecular tests that are designed to improve the diagnostic accuracy of cytology samples such as fine needle aspirates (FNAs), helping to increase the diagnostic utility of these minimally invasive alternatives to surgical biopsy. Veracyte aims to develop products that enable doctors to make better and more efficient treatment decisions that improve patient care and provide cost savings to the healthcare system.
Winnie H. Wan, PhD Executive Chair, CEO and Co-Founder Oncohealth
Dr. Wan is an industry veteran with extensive experience in launching and building life science companies and has successfully commercialized disruptive technologies from inception. These include the analytical systems for drug development at ForteBio, Inc., the anatomical pathology systems for cancer diagnosis at Becton Dickinson, the cell analysis systems at Guava Technologies, Inc., and the HIV drug testing model at SyStemix, Inc. Dr. Wan previously held CEO or executive management positions at BEING Biopharma, Inc., ForteBio, Inc., GeneTrol BioTherapeutics, Becton Dickinson’s Cellular Imaging System Division, Systemix, Inc., etc. She currently serves on the Board of Pediatric Bioscience and the Valley Medical Center Foundation. She received her B.A. from Skidmore College; her Ph.D. in Biochemistry from Yale University, and her M.B.A. from Columbia University and her post-doctoral training in cell biology at Rockefeller University.
OncoHealth Corporation’s mission is to enhance women’s health through better diagnostic testing and screening. OncoHealth plans to commercialize unique proprietary tests for cervical cancer and other cancers associated with human papillomavirus (HPV). By directly differentiating the stages of cancer progression, OncoHealth’s tests will enable clinicians to triage HPV infected patients and select the most effective treatmentsa capability that the Pap smear and existing molecular diagnostic tests cannot provide. The company also can leverage its proprietary technology to produce a full product line of unique test applications for other HPV-associated cancers, including anal, oral, laryngeal, vulva, penile, and vaginal cancers. OncoHealth maintains a strong patent portfolio including HPV biomarkers for detection of HPV and cervical cancer.